Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA, GSK put Avandia pharmacy exit plan in place

This article was originally published in Scrip

Executive Summary

As of 18 November, GlaxoSmithKline's once-top selling Type II diabetes drug Avandia (rosiglitazone), and its related products Avandamet (rosiglitazone and metformin) and Avandaryl (rosiglitazone and glimepiride), no longer will be available in US retail pharmacies, with the only access to the drugs available by mail order to patients already enrolled in a tightly controlled restricted access program, the US FDA and the company said on 18 May.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013001

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel